Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$85.39 USD

85.39
38,208

-1.01 (-1.17%)

Updated May 28, 2024 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LGND

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Ligand Pharmaceuticals Incorporated [LGND]

Reports for Purchase

Showing records 681 - 700 ( 717 total )

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 681

12/05/2012

Company Report

Pages: 11

Highlights From Analyst Day; Ligand Ready for Spotlight; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 682

11/26/2012

Industry Report

Pages: 9

Healthcare -ASH 2012 Preview: Expecting Exciting Data in Atlanta

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 683

11/20/2012

Daily Note

Pages: 12

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 684

11/19/2012

Company Report

Pages: 8

Significant Market Opportunity Added to Promacta with HepC Approval

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 685

11/07/2012

Company Report

Pages: 7

We reiterate our BUY recommendation and have raised our price target to $25.50.

Provider: GRIFFIN SECURITIES, INC.

Analyst: MARKEY K

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 686

11/06/2012

Daily Note

Pages: 22

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 687

11/06/2012

Company Report

Pages: 6

3Q12 Results; Fast Steps Towards Profitability, Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 688

11/05/2012

Daily Note

Pages: 18

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 689

11/02/2012

Company Report

Pages: 4

Positive Signs from Kyprolis Launch; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 690

10/25/2012

Company Report

Pages: 6

Merck hits a milestone and pays $2 million

Provider: GRIFFIN SECURITIES, INC.

Analyst: MARKEY K

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 691

10/23/2012

Daily Note

Pages: 14

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 692

10/22/2012

Company Report

Pages: 6

Milestone Payment and Revenue Shifting; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 693

08/14/2012

Company Report

Pages: 8

Griffin Securities Updates Coverage on Ligand Pharma. (LGND)

Provider: GRIFFIN SECURITIES, INC.

Analyst: MARKEY K

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 694

08/09/2012

Daily Note

Pages: 19

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 695

08/09/2012

Company Report

Pages: 6

2Q12 Results; Looking for Strong Kyprolis Launch and Promacta Approval

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 696

07/25/2012

Daily Note

Pages: 20

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 697

07/25/2012

Company Report

Pages: 4

Promacta Granted HepC Priority Review; See Next Round of Upside to Ligand

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 698

07/23/2012

Daily Note

Pages: 11

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 699

07/20/2012

Daily Note

Pages: 10

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 700

07/20/2012

Company Report

Pages: 4

Kyprolis Approved, Next Revenue Stream Appears Locked In

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party